R230C and C230C Variants of ABCA1 and Glyburide Response
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of the study is to know if the R230C and C230C variants of the ATP-binding cassette transporter A1 (ABCA1) gene are associated with a smaller glucose lowering effect compared to the wild type allele (R230R) in patients with type 2 diabetes.
| Condition | Intervention | Phase |
|---|---|---|
|
Type 2 Diabetes |
Drug: Glyburide |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Basic Science |
| Official Title: | Effect of the R230C Variant of the ATP-binding Cassette Transporter A1 (ABCA1) Gene on the Response to Treatment With Glibenclamide in Patients With Type 2 Diabetes Mellitus |
- Change in plasma fasting glucose [ Time Frame: 20 weeks ] [ Designated as safety issue: No ]The effects of the alleles under study on the glucose lowering effect of glyburide will be assessed in 20 week study. Diet and exercise will be controlled per protocol
- HbA1c levels [ Time Frame: 20 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 94 |
| Study Start Date: | March 2011 |
| Estimated Study Completion Date: | December 2011 |
| Estimated Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Glyburide
Patients in which the fasting glucose persisted above the treatment goal (fasting glucose <126 mg/dl) after a 4 week diet period will receive glyburide. The dose of the medication will be adjusted based on the results of fasting glucose values. At each visit patients will return the leftover tablets; counts of the tablets will be the method for measuring the adherence to treatment. The medical study participants who decided to doses of glibenclamide will not know the allele of ABCA1 gene under study.
|
Drug: Glyburide
Patients in which the fasting glucose persisted above the treatment goal ( fasting plasma glucose above 126 mg/dl) will receive glyburide. The dose of the medication will be adjusted based on the result of blood glucose using the following table: Fasting glucose 126 to 140 mg/dl: 2.5 mg/day (half tablet in the morning) 141 to 180 mg/dl: 5 mg/day (a tablet in the morning) 181 220 mg/dl: 7.5 mg/day (a tablet in the morning and half tablet per night) 221 to 250 mg/dl: 10 mg/day (a tablet in the morning) and a tablet in the evening. |
Detailed Description:
Specific objectives:
In patients with type 2 diabetes stratified by the existence of the risk alleles (R230C/C230C) or the wild variant (R230R) of ABC-A1, compare the changes resulting from the treatment with glibenclamide on following continuous variables:
- Fasting glucose
- Percentage reduction
- Hemoglobin A1c,
- Cholesterol, triglycerides, HDL cholesterol, LDL cholesterol
- Weight
In patients with type 2 diabetes stratified by the existence of the risk alleles (R230C/C230C) or the wild variant (R230R) of ABC-A1, compare the changes resulting from the treatment with glibenclamide on following binomial variables:
- Number of cases that reach fasting plasma glucose lower than 110 mg/dl
- Number of cases that reach an HbA1c less than 7%
Eligibility| Ages Eligible for Study: | 20 Years to 79 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adults 20 to 79 years
- Body mass index >18 and 39.9 ≤
- Men or women
- Mexicans mestizos.
- Moderate hyperglycemia (126 to 250 mg/dl and HbA1c levels between 7 and 10%) despite being treated with a dietary program in combination or not with metformin (2 g/d).
Exclusion Criteria:
- Patients with chronic complications of diabetes: ischemic heart disease, stroke, proliferative retinopathy or blindness, albuminuria, chronic diarrhea, gastroparesis, non-traumatic amputation of lower limbs.
- Patients with any monogenic syndrome, obesity, diabetes or hypoalphalipoproteinemia
- Patients with acquired diseases that produce secondarily obesity or diabetes.
- Treatment with anorexigenics or accelerate weight loss at the time of the selection.
- Cardiovascular event in the 6 months prior to study entry.
- Steroids, chemotherapy, immunosuppressive or radiotherapy.
- Infections or concurrent acute diseases.
- Catabolic diseases such as cancer or AIDS
- Pregnancy
Contacts and Locations| Contact: Carlos A. Aguilar-Salinas, MD | 52-55-56554523 | caguilarsalinas@yahoo.com |
| Mexico | |
| Instituto Nacional de Ciencias Medicas y Nutricion | Recruiting |
| Mexico City, DF, Mexico, 14000 | |
| Contact: Carlos A Aguilar-Salinas, MD 52-55-56554523 caguilarsalinas@yahoo.com | |
| Sub-Investigator: Roberto Medina-Santillan, PhD | |
| Sub-Investigator: Liliana Muñoz, MD | |
| Principal Investigator: | Carlos A Aguilar-Salinas, MD | Instituto Nacional de Ciencias Medicas y Nutricion |
More Information
No publications provided
| Responsible Party: | Carlos Aguilar, Vice Head of the Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
| ClinicalTrials.gov Identifier: | NCT01456650 History of Changes |
| Other Study ID Numbers: | INNSZ-ABCA1 |
| Study First Received: | October 19, 2011 |
| Last Updated: | October 20, 2011 |
| Health Authority: | Mexico: Ethics Committee |
Keywords provided by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran:
|
Type 2 diabetes ABCA1 alleles Glyburide |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Glyburide Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013